Safinamide is an oral α-aminoamide derivate marketed for the treatment of PD with both dopaminergic properties, namely highly selective and reversible inhibition of MAO-B, and nondopaminergic properties, namely selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release [3]. Here, MAOB is linked to Parkinson disease.